Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
209,618,986
-
Number of holders
-
110
-
Total 13F shares, excl. options
-
100,143,382
-
Shares change
-
+9,596,626
-
Total reported value, excl. options
-
$764,063,804
-
Value change
-
+$73,654,467
-
Put/Call ratio
-
72.79%
-
Number of buys
-
58
-
Number of sells
-
-33
-
Price
-
$7.63
Significant Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) as of Q3 2018
127 filings reported holding BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share as of Q3 2018.
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) has 110 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 100,143,382 shares
of 209,618,986 outstanding shares and own 47.77% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (15,103,081 shares), JANUS HENDERSON GROUP PLC (12,250,161 shares), RA CAPITAL MANAGEMENT, LLC (9,234,692 shares), BlackRock Inc. (8,769,856 shares), GREAT POINT PARTNERS LLC (7,978,275 shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (6,910,789 shares), Vanguard Group Inc (5,798,229 shares), JENNISON ASSOCIATES LLC (3,850,003 shares), FMR LLC (3,753,803 shares), and STATE STREET CORP (3,395,701 shares).
This table shows the top 110 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.